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Abstract
Background—Hypertension and associated chronic diseases impose enormous and growing 
health and economic burdens worldwide. The objective of this study was to investigate the cost-
effectiveness (CE) of a hypertension control program in China.
Methods—We collected information on program costs and health outcomes in three community 
health centers over a 1-year period. The participants were 4902 people with hypertension (systolic 
blood pressure [SBP] ≥140 mm Hg and/ or diastolic blood pressure [DBP] ≥90 mm Hg, or on 
hypertension medication) aged 18 years and older. The SBP and DBP changes in the populations 
were estimated from a random sample of 818 participants by conducting face-to-face interviews 
and physical examinations. We derived CE measures based on the costs and effects on health 
outcomes.
Findings—The total cost of implementing the intervention was Renminbi (RMB) 240 772 yuan 
(US$35 252), or 49 yuan (US$7.17) per participant in 2009. On average, SBP decreased from 143 
to 131 mm Hg (P < .001) and DBP decreased from 84 to 78 mm Hg (P < .001), the SBP decreases 
ranged from 7.6 to 17.8 mm Hg and DBP decreases ranged from 3.9 to 8.3 mm Hg. CE ratios 
ranged from RMB 3.6 to 5.0 yuan (US$0.53-US$0.73) per person per mm Hg SBP decrease, and 
from RMB 6.3 to 9.7 yuan (US$0.92-US$1.42) per person per mm Hg DBP decrease.
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Interpretation—Per capita costs varied widely across the communities, as did changes in SBP 
and DBP, but CE was similar. The findings suggest (a) a positive correlation between per capita 
costs and program effectiveness, (b) differences in intervention levels, and (c) differences in health 
status. CE results could be helpful to policy makers in making resource allocation decisions.
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Introduction
Hypertension, a major risk factor for heart disease and stroke, is a growing public health 
problem as its prevalence is high and increasing worldwide.1–3 In China, for example, about 
29% of men and 26% of women in 2000 were hypertensive (systolic blood pressure ≥140 
mm Hg, diastolic blood pressure ≥90 mm Hg, and/or use of antihypertension medications). 
Only 9 years later, the prevalence of hypertension had increased to more than 39% among 
adults older than 35 years.4,5 More than 62% of strokes and 49% of ischemic heart disease 
were attributable to hypertension.6 The morbidity and mortality due to these chronic 
conditions have been increasing rapidly in recent decades.7,8
In addition, hypertension and associated chronic diseases, such as heart disease and stroke, 
impose an enormous economic burden in China. For example, in 2002, the direct medical 
costs of hypertension exceeded Renminbi (RMB) 20 billion yuan. Additionally, the direct 
medical costs of coronary heart disease and stroke were RMB 15.7 billion yuan and 24.3 
billion yuan, respectively, and more than 47% (RMB 19.1 billion yuan) of the total medical 
costs of the 2 chronic diseases were attributable to hypertension.9 Therefore, prevention and 
control of hypertension is a public health priority for improving population health and 
containing the economic burden of chronic diseases. It is a pressing need to develop and 
implement cost-effective strategies to combat the hypertension epidemic in China.
Many intervention programs have been developed and implemented for hypertension control 
and prevention around the world. Some studies have conducted analyses to demonstrate cost 
savings and cost-effectiveness of strategies intended to ameliorate hypertension. For 
example, strategies shown to be cost-effective include a nurse-administered, tailored 
behavioral intervention in the United States,10–12 a national hypertension prevention and 
control program in Israel,13 a national hypertension treatment program in Germany,14 an 
elderly health examination program including hypertension screening in Taiwan,15 an 
adherence-improving program (the Medication Events Monitoring System) in hypertensive 
patients in the Netherlands,16 guidelines for antihypertensive care in Finland,17 and 
ambulatory blood pressure monitoring in Spain.18
In China, however, no studies have documented cost savings or cost-effectiveness of 
programs intended to prevent and control hypertension. Given the enormous health and 
economic burden of hypertension, such information could have important implications for 
public health in China. Policy makers and public health officials could use scientific 
evidence of cost and cost-effectiveness to make wise decisions about resource allocation. 
This study attempts to fill the gap by investigating the cost-effectiveness of hypertension 
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control programs implemented in community health centers as part of an integrated project 
sponsored by China Ministry of Health to control chronic diseases.
Methods
Intervention
The integrated project “Central Government’s Transfer Payments to Local Governments for 
Chronic Disease Intervention and Control” covers 64 communities across China. The project 
is implementing an intervention consisting of the following components: (a) classify the 
patients into 4 groups (ie, low, moderate, high, very high risk), based on their blood 
pressure, number of comorbidities, and risk factors (eg, smoking and drinking); (b) conduct 
diet, exercise, smoking, and drinking interventions consisting of educational sessions, 
supervision, and face-to-face consultation as necessary; (c) standardize drug therapies 
according to 2005 Chinese national guidelines for hypertension prevention and control; (d) 
conduct follow-up visits on a regular basis—once every 3 months for low-risk group, once 
every 2 months for moderate-risk group, and once a month for high- and very-high-risk 
groups; and (e) provide other services, such as physician recommendations, if necessary.
For this study, we selected 3 community health centers that are receiving the implementation 
based on geographic location, demographic characteristics, and availability and/ or 
feasibility of data collection. All three are located in urban settings: one community health 
center is located in Beijing city, representing regions of north and north central China; one is 
in Hangzhou city of Zhejiang Province, representing regions of south and southeast China; 
and one is located in Chengdu city of Sichuan Province, representing the region of 
southwest China. The 3 community health centers served 192 000 residents in the regions 
(Beijing 72 000, Hangzhou 42 000, and Chengdu 78 000) with a total of 286 employees 
(Beijing 119, Hangzhou 122, and Chengdu 45), including physicians (37%), nurses (26%), 
prevention specialists (9%), pharmacists (11%), and others (17%).
Eligibility for this cost-effectiveness study was based on age (18 years or older) and 
hypertension status (at least 3 months of receiving hypertension interventions at one of the 
community health centers) during the period September 2008 to August 2009. Hypertension 
was defined as systolic blood pressure (SBP) ≥140 mm Hg, diastolic blood pressure (DBP) 
≥90 mm Hg, or with a past medical history of hypertension but with normal blood pressure 
when taking antihypertensive drug therapy. We excluded those with serious complications 
and comorbidities such as stroke and diabetes, physical limitations, and mental disorders.
A sample of 860 patients at the 3 centers was selected randomly for this study. Participants 
provided informed consent and voluntarily agreed to take part in the cost-effectiveness 
study. From the 860 participants, 818 valid questionnaires were received. Of the 818 
respondents, 336 were men (41.1%) and 482 were women (58.9%); the mean age was 66.3 ± 
10.6 years.
Calculation of Intervention Costs
We derived the costs of the hypertension intervention funded by the program “Central 
Government’s Transfer Payments to Local Governments for Chronic Disease Intervention 
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and Control” by estimating the labor costs, variable costs, and fixed costs of the 
intervention. Calculations were based on recommendations from China’s Fudan University 
and the World Health Organization.19,20 Medication costs were not included as intervention 
costs because they were normally paid for by the participants’ insurance or other sources 
and because the government’s integrated project did not cover the medications. We 
determined that this was appropriate for the cost-effectiveness analysis from a public health 
care perspective.
Costs of labor were based on the annual income data prorated by the proportion of time that 
workers at the community health centers devoted to the intervention program. Annual 
income figures included salary, bonus, welfare allowance, and social security income. The 
hours working on the hypertension intervention were estimated using medical records for all 
hypertension intervention activities. The costs of labor were usually categorized as variable 
costs. However, most health care workers were permanent government employees. Their 
annual income might account for a significant proportion, for example, nearly half, of the 
intervention costs. Thus, we keep the costs of labor as a stand-alone category.
Variable costs included the costs of printing materials, health education and promotion 
sessions, low-value consumable goods, utility expenses, and other costs related to the 
hypertension intervention.
Fixed costs included the cost of depreciation on fixed assets such as buildings, vehicles, and 
equipment of various kinds relevant to the hypertension intervention. The straight-line 
depreciation method was used to assess depreciation cost for fixed assets. First, the service 
life and the purchase price of the construction, equipment, and fixtures used in the 
hypertension intervention program were obtained, and then the annual depreciation cost was 
calculated by dividing the total cost (price) by the expected life of the asset. Second, the 
engaged time of these equipment and fixtures on hypertension intervention were determined 
by an apportionment ratio (percentage of time used for hypertension control).
Outcome Measures
The outcomes were measured SBP and DBP of the participants, estimated from the random 
sample of 818 patients at the 3 community health centers. For each participant in the sample, 
the blood pressure was measured 3 times before the intervention and 3 times after the 
intervention. The average of the 3 measures at each time point was used for the data 
analysis. Detailed characteristics of the participants are presented in Table 1.
Statistical Methods
The cost data collected were numbered, sorted, validated, and processed with Excel 2003 
software. Epidata3.1 was adopted to establish a database for the questionnaire survey and its 
subsequent data input, whereas SPSS 13.0 was used for data cleaning and statistical 
analysis. The statistical methods used were descriptive analysis, t test, and variance analysis.
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Results
Intervention Costs
The total program costs were RMB 240 772 yuan (US$35 252) for the hypertension 
intervention at the 3 community health centers; 59 091 yuan (US$8652) in Beijing, 108 353 
yuan (US$15 864) in Hangzhou, and 73 328 yuan (US$10 736) in Chengdu (Table 2). 
Overall, the biggest component of the cost was variable costs, which accounted for more 
than half of the total costs. In Beijing, the variable cost accounted for 75% of the 
intervention costs. In Hangzhou, the labor costs were the main component of the program 
cost. Across the 3 community health centers, labor costs ranged from 13.8% to 49.4% of 
total program cost, variable cost from 43.7% to 74.6%, and fixed cost from 6.9% to 11.6%.
From September 2008 to August 2009, the 3 community health centers served a total of 
4902 hypertensive patients: Beijing 1603, Hangzhou 1358, and Chengdu 1941. The annual 
per capita cost of the hypertension intervention at all the community health centers was 
RMB 49 yuan (US$7.17), ranging from 37 yuan (US$5.42) in Beijing to 80 yuan (US
$11.71) in Hangzhou.
Health Outcome Effects
After the 1-year intervention, mean SBP dropped by 12.3 mm Hg, with the drop ranging 
from 7.6 mm Hg in Chengdu to 17.8 mm Hg in Hangzhou. Mean DBP decreased by 6.2 mm 
Hg, ranging from 3.9 mm Hg in Chengdu to 8.3 mm Hg in Hangzhou. All reductions of the 
blood pressure were statistically significant (Table 3).
Cost-Effectiveness Ratio
The cost-effectiveness ratio for the intervention across all three sites was RMB 4.0 yuan (US
$0.59) per mm Hg SBP decrease and, at the same time DBP decreased by about 0.5 mm Hg 
(Table 4). The cost-effectiveness ratios ranged from RMB 3.6 yuan (US$0.53) in Beijing to 
5 yuan (US$0.73) in Chengdu per mm Hg SBP decrease. Using DBP measures, the cost-
effectiveness ratio ranged from RMB 6.3 yuan (US$0.92) in Beijing to 9.7 yuan (US$1.42) 
in Chengdu. In extreme cases, the cost could be as low as RMB 2.1 yuan (US$0.31) or as 
high as 10.5 yuan (US$1.54) for a 1 mm Hg reduction in SBP, or RMB 4.5 yuan (US$0.66) 
to 20.5 yuan (US$3.00) for 1 mm Hg DBP reduction.
Discussion
In this study, we examined the costs and effectiveness of an intervention for hypertension 
control in 3 community health centers. As far as we know, this is the first empirical analysis 
of costs and cost-effectiveness of interventions for hypertension control at community levels 
in China. Our results showed that there was a large variation in per capita program costs and 
a large variation in average SBP and DBP reductions across communities. The large 
variations suggest a great potential in reducing cost and increasing SBP and DBP reductions 
in some communities.
More than 54% of the program cost was variable cost, which presents the best opportunity 
for reducing costs and improving cost-effectiveness of the intervention. However, in one 
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center (Hangzhou), nearly half (49.4%) of the program cost was labor cost. This suggests 
that labor cost was also an important factor affecting the cost-effectiveness of the 
intervention in some areas.
In addition, the components of program cost varied greatly from site to site; for example, 
only 13.8% of the intervention cost was labor cost in Beijing, but it comprised 49.4% of 
total cost in Hangzhou. The differences in the cost components may reflect the differences in 
intervention intensity or contents. For example, patient assessment reports were mostly 
printed in color in Beijing to improve patient compliance with the intervention. This 
subsequently increased the variable costs in this center. In Hangzhou, the follow-up visits 
were mainly (about 80%) home visits. In-home visits usually took longer time than other 
forms of follow-up visits such as telephone and outpatient visits. Thus, the labor cost was 
much higher in Hangzhou than in other 2 centers. These variations signal a need to explore 
the reasons behind such differences.
We also found that the blood pressure reductions attributable to the program were 
significant. On average, the SBP decreased by 12.3 mm Hg (P < .001) from 143 mm Hg 
before the intervention to 131 mm Hg after the intervention. And the reduction was as great 
as 17.8 mm Hg in Hangzhou. The DBP decreased by 6.2 mm Hg (P < .001), ranging from 
3.9 mm Hg in Chengdu to 8.3 mm Hg in Hangzhou. These reductions were larger than many 
interventions in other countries where many interventions had SBP reduction of less than 10 
mm Hg regardless of the duration of the interventions.21–23 Therefore, the interventions 
implemented at the community health centers were very effective in China. In Hangzhou, 
both SBP and DBP decreased the most among the 3 intervention sites. This might be 
because of poor health status at the beginning of the intervention such as having higher 
blood pressure than patients in other 2 sites. This might also explain the fact that the costs of 
labor were higher in Hangzhou than in other sites. The significant blood pressure reduction 
is likely to have a substantial impact on public health because even a small decrease in 
population blood pressure is likely to result a substantial reduction in cardiovascular disease 
and mortality.24 This is further supported by the fact that the morbidity and mortality due to 
the chronic diseases have been high and becoming more prevalent in China.7,8
Finally, we found that the community with the highest per capita program costs also had the 
best health outcomes, that is, largest decreases in SBP and DBP. For example, the per capita 
cost in Hangzhou was RMB 80 yuan (US$11.71), more than twice that in Beijing (37 yuan, 
US$5.42) or Chengdu (38 yuan, US$5.56). In terms of health outcome effect, participants in 
Hangzhou had a mean reduction of 17.8 mm Hg SBP and 8.3 mm Hg DBP, and the 
reductions were nearly double those achieved in Beijing, and more than double those in 
Chengdu. Therefore, the cost-effectiveness ratios did not vary greatly, as the cost per mm 
Hg reduction ranged from RMB 3.6 yuan (US$0.53) in Beijing to 5.0 yuan (US$0.73) in 
Chengdu for SBP, and Hangzhou was in between, with a cost-effectiveness ratio of 4.5 yuan 
(US$0.66). The patterns were similar for DBP. The mean DBP reduction in Hangzhou was 
8.3 mm Hg, compared with 5.9 mm Hg in Beijing, and 3.9 mm Hg in Chengdu. The cost-
effectiveness ratio for DBP ranged from RMB 6.3 yuan (US$0.92) in Beijing to 9.7 yuan 
(US$1.42) in Chengdu per mm Hg reduction in DBP. As was the case with SBP, the cost-
effectiveness ratio of Hangzhou was 9.6 yuan (US$1.41), between that of the other 2 sites. 
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These findings suggest a positive correlation between program investment and program 
impact. Program investment might be a good indicator of program intensity, quality, or both. 
Because we have not noted any such information in the literature for comparisons, we 
cannot make any claims about whether the cost-effectiveness ratios indicated that the 
intervention investments for hypertension control were better or worse uses of government 
funds compared with other various government programs.
The costs and cost-effectiveness information presented in this study could be used by policy 
makers and public health officials in developing government policies and making resource 
allocation decisions to promote population health. We hope our study will convince more 
researchers to explore program cost and cost-effectiveness information in public health 
areas.
Limitations
Our study had several limitations that should be considered in interpreting our findings. 
First, we used data from only 3 community health centers. Although they were located in 
different geographic regions, all 3 were in urban areas. The small number of community 
centers and the relatively small sample size may limit the generalization of the results to the 
national level or rural areas. Many studies have explored issues of growing health burden 
associated with hypertension in rural China.25–28 There is a pressing need to conduct 
economic evaluation studies focusing on rural residents. Second, we did not include 
socioeconomic factors, such as household income, age, sex, education, or employment status 
in the data analysis. All these characteristics differed greatly across the community health 
centers and affected the cost, health outcomes, and cost-effectiveness of the interventions. 
Incorporating these variables into cost-effectiveness analysis should provide more insightful 
information to policy makers and public health practitioners. Third, the China Ministry of 
Health sponsored the intervention, which was a continuous project for several years. We 
arbitrarily selected a 1-year period for this study (September 2008 to August 2009.) This 
might affect the cost calculation since government investment may not be spent evenly over 
the project years. A follow-up study is needed to validate the cost-effectiveness results.
Finally, we only used blood pressure as a health outcome. We were unable to evaluate the 
effect of the intervention on behavioral outcomes such as antihypertensive medication 
adherence and health consequences of hypertension such as cardiovascular disease, stroke or 
quality-adjusted life years, which likely would be relevant information for policy makers 
working on public health policies. Further investigations of the intervention’s effects on 
these outcomes should strengthen the policy implications of the information on cost and 
cost-effectiveness.
Conclusions
This study examined detailed information on cost and cost-effectiveness of an intervention 
for hypertension control using data collected in 3 community health centers located in 3 
different regions of China. This was the first empirical study, as far as we know, to examine 
the costs and cost-effectiveness of a hypertension control intervention in China. Our results 
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showed that the hypertension intervention at community health centers was effective in 
reducing blood pressures although per capita costs of the intervention varied widely across 
communities. Because China is a developing country and resources for public health are 
extremely limited, careful choices must be made in allocating scarce resources. This study 
provided much-needed cost and cost-effectiveness information that should be helpful to 
policy makers and public health professionals as they make decisions about allocating 
resources and developing cost-effective interventions for hypertension control.
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Table 3
Mean Blood Pressures (mm Hg) Before and After 1-Year Intervention (N = 818).
Before After Difference Summary Statistics
Systolic blood pressure 143.3 ± 16.6 131.0 ± 12.4 12.3 ± 14.8 t = 23.69 (P < .001); F = 39.33 (P < .001)
 Beijing 140.7 ± 10.1 130.4 ± 11.4 10.3 ± 10.8
 Hangzhou 154.0 ± 16.1 136.2 ± 14.1 17.8 ± 15.9
 Chengdu 132.6 ± 14.4 125.0 ± 7.5 7.6 ± 15.0
Diastolic blood pressure 84.4 ± 10.1 78.3 ± 8.0 6.2 ± 10.2 t = 17.38 (P < .001); F = 13.08 (P < .001)
 Beijing 85.5 ± 8.9 79.6 ± 8.6 5.9 ± 9.2
 Hangzhou 88.1 ± 10.0 79.8 ± 8.4 8.3 ± 11.0
 Chengdu 78.8 ± 8.9 74.9 ± 5.4 3.9 ± 9.7
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Table 4
Cost-Effectiveness of the Community Health Centers in Hypertension Control.
Cost per mm Hg SBP Reduction, Renminbi yuan (US
$)a
Cost per mm Hg DBP Reduction, Renminbi yuan 
(US$)
Overall 4.0 (0.59) 7.9 (1.16)
 Beijing 3.6 (0.53) 6.3 (0.92)
 Hangzhou 4.5 (0.66) 9.6 (1.41)
 Chengdu 5.0 (0.73) 9.7 (1.42)
Extreme cases
 Best case scenariob 2.1 (0.31) 4.5 (0.66)
 Worst case scenarioc 10.5 (1.54) 20.5 (3.00)
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
a
Based on average rate of exchange of US$1 = Renminbi 6.8307 yuan in 2009. Source: http://www.federalreserve.gov/release/g5a.
b
Based on the lowest per capita cost and greatest blood pressure reduction of the community health centers.
c
Based on the highest per capita cost and smallest blood pressure reduction of the community health centers.
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